参考文献
1: Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3(12):1763-7. Review. PubMed PMID: 12528314.
2: Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM; Neurologic AIDS Research Consortium.. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002 Nov 26;59(10):1568-73. PubMed PMID: 12451199.
3: Bjugstad KB, Flitter WD, Garland WA, Philpot RM, Kirstein CL, Arendash GW. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. J Neurovirol. 2000 Dec;6(6):478-91. PubMed PMID: 11175320.
4: Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. Brain Res. 2001 Mar 2;893(1-2):95-103. PubMed PMID: 11222997.
5: Hensley K, Robinson KA, Pye QN, Floyd RA, Cheng I, Garland WA, Irwin I. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281(2-3):179-82. PubMed PMID: 10704772.
6: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. June 2002. Methods Find Exp Clin Pharmacol. 2002 Jun;24(5):291-327. Review. PubMed PMID: 12168506.
7: Bjugstad KB, Flitter WD, Garland WA, Su GC, Arendash GW. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 1998 Jun 8;795(1-2):349-57. PubMed PMID: 9622673.
